Charles Paul, MD
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,425 of the $3,990 with a category attached, or 60.8%. Boston Scientific accounts for 85.1% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2022 at $1,535 and has fallen 96.4% since, to $56 in 2025.
Across 41 payments — averaging $97.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- Axonics, Inc.$440
- C. R. Bard, Inc. & Subsidiaries$83
- Pfizer$28
- Tolmar, Inc.$27
- Teleflex LLC$15
What the payments were for
- Speaking & faculty fees$832%
- Travel & lodging$2,42561%
- Food & beverage$1,48337%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 26 | $3,396 |
| Axonics, Inc. | 10 | $440 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $83 |
| Pfizer | 2 | $28 |
| Tolmar, Inc. | 1 | $27 |
| Teleflex LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GENERAL KIDNEY STONE DISEASE$1,272
- GENERAL - THERAPIES$1,259
How this compares
$3,990 in reported general payments places this provider in the 65th percentile of 114 urology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 15 | $6,515 |
| Tamsulosin Hcl | 410 | $4,936 |
| Finasteride | 350 | $4,209 |
| Trospium Chloride | 48 | $2,668 |
| Potassium Citrate ErPotassium Citrate | 33 | $2,523 |
| Estradiol | 17 | $1,004 |
| Oxybutynin Chloride ErOxybutynin Chloride | 73 | $740 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 33 | $610 |
| Cephalexin | 117 | $505 |
| Levofloxacin | 31 | $329 |
| Oxycodone Hcl | 19 | $63 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $52 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 11 | $25 |
Paid to pharmacies, not to this prescriber.
Other urology in Ames
- Damon DycheAmes$4K
- Garrett KorrectAmes$2K
- Vignesh PackiamIowa City$112K
- Annah VollstedtIowa City$66K
- Bradley EricksonIowa City$65K
- Michael OdonnellIowa City$62K
- Kevin BirusinghDes Moines$59K
- Ryan DornbierClive$55K
- Alexandria HertzIowa City$53K
- John BuieIowa City$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.